<p>Compugen Ltd.（纳斯达克代码：CGEN - 获取免费报告）首席执行官 Eran Ophir 于 4 月 1 日星期三出售了 5,625 股公司股票。股票以平均价格 2.21 美元出售，总价值为 12,431.25 美元。交易后，首席执行官直接持有公司 11,375 股，价值约为 25,138.75 美元。这代表其持股比例下降了 33.09%。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
<h2>Compugen 股票上涨 2.7%</h2>
<p>CGEN 股票在周五开盘价为 2.26 美元。该股票的 50 日移动平均价格为 1.96 美元，200 日移动平均价格为 1.77 美元。该股票的市值为 2.1368 亿美元，市盈率为 6.11，贝塔值为 2.77。Compugen Ltd.的 52 周低点为 1.13 美元，52 周高点为 2.38 美元。</p>
<p>Compugen（纳斯达克代码：CGEN - 获取免费报告）最近于 3 月 2 日星期一发布了季度财报。这家生物技术公司报告该季度每股收益为 0.60 美元，超出分析师一致预期的 0.05 美元，超出幅度为 0.55 美元。该公司在该季度的收入为 6733 万美元，而分析师预期为 1430 万美元。Compugen 的股本回报率为 55.68%，净利润率为 48.57%。分析师预计 Compugen Ltd.在当前财年将发布每股收益-0.03 美元。</p>
<h2>分析师评级上调与下调</h2>
<p>几家券商对 CGEN 发布了报告。华尔街 Zen 在 3 月 7 日的研究报告中将 Compugen 的评级从 “持有” 上调至 “买入”。HC Wainwright 在 1 月 7 日的报告中开始覆盖 Compugen 股票，给予 “买入” 评级和 4.00 美元的目标价。Truist Financial 在 3 月 25 日的研究报告中将 Compugen 的评级上调至 “强力买入”。最后，Weiss Ratings 在 1 月 21 日的报告中重新发布了 Compugen 的 “卖出（d-）” 评级。一位分析师对该股票给予了强力买入评级，一位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Compugen 目前的平均评级为 “适度买入”，共识目标价为 4.00 美元。</p>
<p><strong>阅读我们对 Compugen 的最新分析</strong></p>
<h2>Compugen 的机构交易</h2>
<p>几家大型投资者最近买入和卖出了 CGEN 股票。Renaissance Technologies LLC 在第四季度将其在 Compugen 的持股增加了 3.7%。Renaissance Technologies LLC 现在拥有 145,6900 股生物技术公司的股票，价值 2,229,000 美元，此前在上个季度又购买了 51,565 股。Jane Street Group LLC 在第二季度将其在 Compugen 的持股增加了 1,077.0%。Jane Street Group LLC 现在拥有 393,191 股生物技术公司的股票，价值 700,000 美元，此前在上个季度又收购了 359,785 股。State Street Corp 在第四季度将其在 Compugen 的持股增加了 3.9%。State Street Corp 现在拥有 393,802 股生物技术公司的股票，价值 603,000 美元，此前在上个季度又收购了 14,701 股。Two Sigma Investments LP 在第三季度将其在 Compugen 的持股增加了 10.6%。Two Sigma Investments LP 现在拥有 197,875 股生物技术公司的股票，价值 291,000 美元，此前在上个季度又收购了 18,929 股。最后，Marshall Wace LLP 在第四季度将其在 Compugen 的持股增加了 135.7%。Marshall Wace LLP 现在拥有 106,304 股生物技术公司的股票，价值 163,000 美元，此前在上个季度又收购了 61,202 股。机构投资者和对冲基金持有该公司 12.22% 的股票。</p>
<h2>关于 Compugen</h2>
<p>（获取免费报告）</p>
<p>Compugen Ltd.（纳斯达克代码：CGEN）是一家临床阶段的治疗发现公司，利用专有的计算发现平台来识别新的免疫肿瘤靶点和生物标志物。该公司结合大规模生物数据集与机器学习算法，以生成和验证新的治疗和诊断候选者。Compugen 成立于 1993 年，总部位于以色列特拉维夫，同时在美国设有办事处，以支持其临床开发和商业合作。</p>
<p>Compugen 的预测发现引擎在计算机中扫描复杂的生物系统，以揭示与癌症进展相关的先前未被识别的通路和免疫检查点。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Compugen 吗？</h2>
<p>在你考虑 Compugen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场意识到之前……而 Compugen 并不在名单上。</p>
<p>虽然 Compugen 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

Compugen医疗

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Compugen Ltd. 首席执行官 Eran Ophir 以每股 2.21 美元的价格出售了 5,625 股，总计 12,431.25 美元，减少了 33.09% 的持股比例。出售后，他持有 11,375 股，估值约为 25,138.75 美元。该交易是在 10b5-1 规则下进行，并已向 SEC 披露。Compugen 的股票上涨 2.7% 至 2.26 美元，市值为 2.1368 亿美元。公司报告每股收益为 0.60 美元，超出预期，营收为 6,733 万美元。分析师对该股票的评级不一，目标价共识为 4.00 美元</p>

<p>Compugen Ltd. (NASDAQ:CGEN - Get Free Report) CEO Eran Ophir sold 5,625 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $2.21, for a total value of $12,431.25. Following the transaction, the chief executive officer directly owned 11,375 shares in the company, valued at approximately $25,138.75. This represents a 33.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p>
<div class="lb-trans"><p>Compugen Ltd.（纳斯达克代码：CGEN - 获取免费报告）首席执行官 Eran Ophir 于 4 月 1 日星期三出售了 5,625 股公司股票。股票以平均价格 2.21 美元出售，总价值为 12,431.25 美元。交易后，首席执行官直接持有公司 11,375 股，价值约为 25,138.75 美元。这代表其持股比例下降了 33.09%。该交易已在与证券交易委员会的法律文件中披露，可以通过此超链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。</p>
</div><h2>Compugen Stock Up 2.7%</h2>
<div class="lb-trans"><h2>Compugen 股票上涨 2.7%</h2>
</div><p>Shares of CGEN stock opened at $2.26 on Friday. The stock's 50-day moving average price is $1.96 and its 200 day moving average price is $1.77. The stock has a market capitalization of $213.68 million, a PE ratio of 6.11 and a beta of 2.77. Compugen Ltd. has a 52-week low of $1.13 and a 52-week high of $2.38.</p>
<div class="lb-trans"><p>CGEN 股票在周五开盘价为 2.26 美元。该股票的 50 日移动平均价格为 1.96 美元，200 日移动平均价格为 1.77 美元。该股票的市值为 2.1368 亿美元，市盈率为 6.11，贝塔值为 2.77。Compugen Ltd.的 52 周低点为 1.13 美元，52 周高点为 2.38 美元。</p>
</div><p>Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million during the quarter, compared to analysts' expectations of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. Analysts expect that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Compugen（纳斯达克代码：CGEN - 获取免费报告）最近于 3 月 2 日星期一发布了季度财报。这家生物技术公司报告该季度每股收益为 0.60 美元，超出分析师一致预期的 0.05 美元，超出幅度为 0.55 美元。该公司在该季度的收入为 6733 万美元，而分析师预期为 1430 万美元。Compugen 的股本回报率为 55.68%，净利润率为 48.57%。分析师预计 Compugen Ltd.在当前财年将发布每股收益-0.03 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several brokerages have issued reports on CGEN. Wall Street Zen raised shares of Compugen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, March 7th. HC Wainwright began coverage on shares of Compugen in a report on Wednesday, January 7th. They issued a &#34;buy&#34; rating and a $4.00 target price on the stock. Truist Financial upgraded shares of Compugen to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Compugen in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Compugen currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $4.00.</p>
<div class="lb-trans"><p>几家券商对 CGEN 发布了报告。华尔街 Zen 在 3 月 7 日的研究报告中将 Compugen 的评级从 “持有” 上调至 “买入”。HC Wainwright 在 1 月 7 日的报告中开始覆盖 Compugen 股票，给予 “买入” 评级和 4.00 美元的目标价。Truist Financial 在 3 月 25 日的研究报告中将 Compugen 的评级上调至 “强力买入”。最后，Weiss Ratings 在 1 月 21 日的报告中重新发布了 Compugen 的 “卖出（d-）” 评级。一位分析师对该股票给予了强力买入评级，一位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Compugen 目前的平均评级为 “适度买入”，共识目标价为 4.00 美元。</p>
</div><p><strong>Read Our Latest Analysis on Compugen</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Compugen 的最新分析</strong></p>
</div><h2>Institutional Trading of Compugen</h2>
<div class="lb-trans"><h2>Compugen 的机构交易</h2>
</div><p>Several large investors have recently bought and sold shares of CGEN. Renaissance Technologies LLC raised its stake in shares of Compugen by 3.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company's stock worth $2,229,000 after buying an additional 51,565 shares during the last quarter. Jane Street Group LLC grew its stake in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock valued at $700,000 after acquiring an additional 359,785 shares during the last quarter. State Street Corp increased its holdings in Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company's stock valued at $603,000 after acquiring an additional 14,701 shares in the last quarter. Two Sigma Investments LP increased its holdings in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company's stock valued at $291,000 after acquiring an additional 18,929 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company's stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了 CGEN 股票。Renaissance Technologies LLC 在第四季度将其在 Compugen 的持股增加了 3.7%。Renaissance Technologies LLC 现在拥有 145,6900 股生物技术公司的股票，价值 2,229,000 美元，此前在上个季度又购买了 51,565 股。Jane Street Group LLC 在第二季度将其在 Compugen 的持股增加了 1,077.0%。Jane Street Group LLC 现在拥有 393,191 股生物技术公司的股票，价值 700,000 美元，此前在上个季度又收购了 359,785 股。State Street Corp 在第四季度将其在 Compugen 的持股增加了 3.9%。State Street Corp 现在拥有 393,802 股生物技术公司的股票，价值 603,000 美元，此前在上个季度又收购了 14,701 股。Two Sigma Investments LP 在第三季度将其在 Compugen 的持股增加了 10.6%。Two Sigma Investments LP 现在拥有 197,875 股生物技术公司的股票，价值 291,000 美元，此前在上个季度又收购了 18,929 股。最后，Marshall Wace LLP 在第四季度将其在 Compugen 的持股增加了 135.7%。Marshall Wace LLP 现在拥有 106,304 股生物技术公司的股票，价值 163,000 美元，此前在上个季度又收购了 61,202 股。机构投资者和对冲基金持有该公司 12.22% 的股票。</p>
</div><h2>About Compugen</h2>
<div class="lb-trans"><h2>关于 Compugen</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.</p>
<div class="lb-trans"><p>Compugen Ltd.（纳斯达克代码：CGEN）是一家临床阶段的治疗发现公司，利用专有的计算发现平台来识别新的免疫肿瘤靶点和生物标志物。该公司结合大规模生物数据集与机器学习算法，以生成和验证新的治疗和诊断候选者。Compugen 成立于 1993 年，总部位于以色列特拉维夫，同时在美国设有办事处，以支持其临床开发和商业合作。</p>
</div><p>Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.</p>
<div class="lb-trans"><p>Compugen 的预测发现引擎在计算机中扫描复杂的生物系统，以揭示与癌症进展相关的先前未被识别的通路和免疫检查点。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Compugen</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compugen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compugen 吗？</h2>
</div><p>Before you consider Compugen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compugen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场意识到之前……而 Compugen 并不在名单上。</p>
</div><p>While Compugen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compugen 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Compugen (NASDAQ:CGEN) CEO Sells $12,431.25 in Stock

Market Beat

Invesco Nasdaq Biotechnology ETF

Compugen（纳斯达克股票代码：CGEN）的首席执行官出售了价值 12,431.25 美元的股票